Maynard Um
-
-
-
-
-
-
-
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
-
-
-
-
-
-
-
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
-
-
-
-
-
-
-
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
-
-
-
-
-
-
-
Jaguar Health meets with FDA on rare disease drug development
-
-
-
-
-
-
-
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
-
-
-
-
-
-
-
Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
-
-
-
-
-
-
-
Jaguar Health (JAGX) to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
